Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

Slides:

Advertisements

Similar presentations

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Advertisements

Pinja Ilmarinen, PhD, Leena E

Asthma Yardstick Annals of Allergy, Asthma & Immunology

Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma Geneviève Racine, Roberto Castano, MD, PhD, André Cartier, MD, Catherine.

The ABCs of Asthma Control

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence Laurent Laforest, MD, PhD, Manon Belhassen, MSc, Gilles Devouassoux,

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Effect of montelukast for treatment of asthma in cigarette smokers

Shyam Joshi, MD, David A. Khan, MD

Jennie Gane, MBChB (Hons), MSc, Roger Buckley, BM BCh, MA, FRCS

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Felix Ratjen, Paul Koker, David E

Practice Notes from the AAAI

Badrul A. Chowdhury, MD, PhD

Safety of Fluticasone Propionate Prescribed for Asthma During Pregnancy: A UK Population-Based Cohort Study Rachel A. Charlton, PhD, Julia M. Snowball,

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Validation of the Pregnancy Asthma Control Test

Timothy J. Craig, DO, H. Henry Li, MD, Marc Riedl, MD, Jonathan A

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Nonadherence to Asthma Treatment: Getting Unstuck

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Peter M. Wolfgram, MD, David B. Allen, MD

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.

Michael E. Wechsler, MD Mayo Clinic Proceedings

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Laura Cordova-Rivera, BPhty(Hons), Peter G. Gibson, MBBS, Paul A

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

A Systematic Review of Patient- and Family-Level Inhaled Corticosteroid Adherence Interventions in Black/African Americans Isaretta L. Riley, MD, MPH,

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Peter König, MD, PhD Journal of Allergy and Clinical Immunology

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Phillip Lieberman, MD, Michael Tankersley, MD

Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? Gennaro Liccardi, MD, Antonello.

Effects of Mometasone, Fluticasone, and Montelukast on Bone Mineral Density in Adults with Asthma Jorge Maspero, MD, Vibeke Backer, DMSci, MD, Ruji Yao,

News & Notes Journal of Allergy and Clinical Immunology

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

The Management of Eosinophilic Esophagitis

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Pinja Ilmarinen, PhD, Leena E

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Sharon Seth, MD, David A. Khan, MD

Cephalosporin Side Chain Cross-reactivity

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

The Journal of Allergy and Clinical Immunology: In Practice

Eckard Hamelmann, MD, Eric D

Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network.

Larry C. Borish, MDa, Harold S

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Daniel Menzies, MBChB, Arun Nair, MBBS, Karen T

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István Laki, MD, Jonathan A. Bernstein, MD, Olaf Schmidt, MD, Georges El Azzi, MD, Petra Moroni-Zentgraf, MD, Ralf Sigmund, Dipl-Math Oec, Eckard Hamelmann, MD, PhD The Journal of Allergy and Clinical Immunology: In Practice Volume 6, Issue 6, Pages 2160-2162.e9 (November 2018) DOI: 10.1016/j.jaip.2018.04.032 Copyright © 2018 The Authors Terms and Conditions

Figure E1 Study design. ICS, Inhaled corticosteroids; LTRA, leukotriene receptor antagonist. The Journal of Allergy and Clinical Immunology: In Practice 2018 6, 2160-2162.e9DOI: (10.1016/j.jaip.2018.04.032) Copyright © 2018 The Authors Terms and Conditions

Figure E2 Patient disposition CONSORT diagram. The Journal of Allergy and Clinical Immunology: In Practice 2018 6, 2160-2162.e9DOI: (10.1016/j.jaip.2018.04.032) Copyright © 2018 The Authors Terms and Conditions

Figure E3 A, Peak FEV1(0-3h) responses at weeks 24 and 48. B, Trough FEV1 responses at weeks 12, 24, and 48. Full analysis set. Adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Error bars are ±standard error. FEV1 common baseline mean ± standard deviation = 1629 ± 393 mL. FEV1, Forced expiratory volume in 1 second; FEV1(0-3h), forced expiratory volume in 1 second within 3 hours after dosing. *P < .05. **P ≤ .001 versus placebo Respimat. The Journal of Allergy and Clinical Immunology: In Practice 2018 6, 2160-2162.e9DOI: (10.1016/j.jaip.2018.04.032) Copyright © 2018 The Authors Terms and Conditions

Figure E4 FEF25-75% responses at weeks 12, 24, and 48. Full analysis set. Adjusted for treatment, country, visit, baseline, treatment-by-visit interaction, and baseline-by-visit interaction. Error bars are ±standard error. FEF25-75% common baseline mean ± standard deviation = 1431 ± 584 mL. FEF25-75%, Forced expiratory flow at 25% to 75% of the forced vital capacity. *P < .05. **P ≤ .001 versus placebo Respimat. The Journal of Allergy and Clinical Immunology: In Practice 2018 6, 2160-2162.e9DOI: (10.1016/j.jaip.2018.04.032) Copyright © 2018 The Authors Terms and Conditions